ANAPTYSBIO, INC
No enriched coverage for $ANAB in the last 7 days.
AnaptysBio (ANAB) reported a $176.4M profit for the first half of 2024, driven by a $181.5M tax benefit. Collaboration revenue grew 23% to $27.5M, and Jemperli royalties increased 25%. Royalties could grow faster as sales reach higher tiers. The company expects $299M from the Sagard arrangement by late 2027. Operating cash flow improved, but costs and litigation risks remain.
AnaptysBio (ANAB) reported Q4 2026 net income of $183.88M, reversing a year-earlier loss. Basic and diluted EPS were $6.06 and $4.93, respectively, with six-month net income at $131M. The shift to profitability raises questions about sustainability and market reaction, as the stock has risen over a year but fallen recently.
U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.
Recent ANAB coverage spans earnings, financial news and regulation.
In the last 30 days, ANAB insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($249K). The most active reporter was RENTON HOLLINGS with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Earnings beat pretax loss, but cash flow remains limited; royalty upside and litigation risk drive near‑term volatility.
Earnings beat expectations and show a profitability inflection, likely supporting short‑term price upside.
Revenue beat supports near‑term optimism.
Earnings beat and upbeat guidance suggest near‑term upside.
Earnings beat driven by non‑recurring tax benefit; underlying operating performance modest.
AlphAI scores every news story that mentions ANAB with an AI model for sentiment and relevance, and aggregates insider trades from ANAPTYSBIO, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
AnaptysBio (ANAB) reported a $176.4M profit for the first half of 2024, driven by a $181.5M tax benefit. Collaboration revenue grew 23% to $27.5M, and Jemperli royalties increased 25%. Royalties could grow faster as sales reach higher tiers. The company expects $299M from the Sagard arrangement by late 2027. Operating cash flow improved, but costs and litigation risks remain.
3 min readAnaptysBio (ANAB) reported Q4 2026 net income of $183.88M, reversing a year-earlier loss. Basic and diluted EPS were $6.06 and $4.93, respectively, with six-month net income at $131M. The shift to profitability raises questions about sustainability and market reaction, as the stock has risen over a year but fallen recently.
2 min readU.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.
2 min readAnaptysBio Inc (ANAB) stock rose 3.8% after reporting Q2 and FY2026 results. Revenue was $27.5M, exceeding expectations of $20M. CEO Daniel Faga highlighted near-term catalysts, including FDA approvals and sales growth. The broader market also saw strength in tech shares.
2 min readAnaptysBio (ANAB) reported net income of $177.3M for Q2 2026, driven by a $181.5M one-time tax benefit. Jemperli sales rose 34% YoY to $644M for H1 2026. The company anticipates Jemperli royalties exceeding $390M annually by 2029. Cash reserves decreased to $364.1M due to operating expenses. ANAB is involved in litigation with GSK and Tesaro over Jemperli rights.
2 min readAnaptysBio (ANAB) reported Q2FY26 adjusted EPS of $(0.11), beating estimates by 76%. Revenue rose 23% YoY to $27.5M, exceeding expectations. Net income surged to $177.3M due to a $181.5M tax benefit. Jemperli sales grew 34% YoY to $644M. Cash position declined to $164.1M.
2 min readAnaptysBio, Inc. (ANAB) filed a Form 10-KT transition report for the period from January 1, 2026, to June 30, 2026, reflecting a change in its fiscal year end from December 31 to June 30. The company disclosed an aggregate market value of $632.7 million in voting common equity held by non-affiliates as of December 31, 2025, and 29.9 million shares of common stock outstanding as of September 16, 2026. The report includes forward-looking statements and risk factors.
1 min readAnaptysBio reported Q2 2026 results, with Jemperli global net sales at $644M, up 34% YoY. Positive AZUR-1 trial results announced, with FDA decision expected in Feb 2027. Litigation with GSK and Tesaro ongoing, with judgment anticipated by Q1 2027. Quimilza FDA decision targeted for Dec 2026. Collaboration revenue increased 25% YoY, driven by Jemperli royalties. Net income from continuing operations was $177.3M for Q2 2026.
3 min readGlobal markets are mixed as crude oil prices and bond yields rise. Saudi Arabia aims to restore half of its East-West pipeline capacity, which was shut due to drone strikes. Markets price in a 58% chance of a 25 bp Fed rate hike. Software and cybersecurity stocks fall, while chipmakers and crypto-exposed stocks rise. Netflix drops after a downgrade, and Nucor declines on weaker earnings guidance. Bitcoin gains over 2% after SEC's digital securities plan.
3 min readAnaptysBio Inc. is set to report Q2 earnings, with investors watching if Jemperli royalty growth can offset a 21% revenue decline. Analysts expect a loss of $0.13 per share on $20.2M revenue. All 11 analysts rate it a Strong Buy, with a mean target of $86.64. Jemperli's FDA priority review for rectal cancer and imsidolimab's regulatory decision in December are key catalysts. The company has a $100M buyback plan and a market cap of $1.67B.
2 min read
